SFSIG
ALNY icon

San Francisco Sentry Investment Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

San Francisco Sentry Investment Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-11
Closed -$1K – 672
2020
Q1 		$1K Hold
11
– – ﹤0.01% 706
2019
Q4 		$1K Hold
11
– – ﹤0.01% 795
2019
Q3 		$1K Buy
+11
New +$870 ﹤0.01% 797
2018
Q4 		– Sell
-10
Closed -$1K – 979
2018
Q3 		$1K Buy
+10
New +$1.01K ﹤0.01% 836

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

San Francisco Sentry Investment Group's ALNY Position: Q2 2020 in Review

San Francisco Sentry Investment Group sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2020, closing a stake of 11 shares — an estimated $1K sold.

San Francisco Sentry Investment Group first reported a position in ALNY in Q3 2018 and held it in 4 quarters. The position peaked at $1K in Q1 2020. 374 funds tracked by Wall St. Rank hold ALNY as of Q2 2020.

  • San Francisco Sentry Investment Group reported no remaining Alnylam Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 11 Alnylam Pharmaceuticals shares in Q2 2020, an estimated $1K.
  • San Francisco Sentry Investment Group first reported a position in Alnylam Pharmaceuticals in Q3 2018 and held it in 4 quarters.
  • San Francisco Sentry Investment Group's Alnylam Pharmaceuticals position peaked at $1K in Q1 2020.
  • 374 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2020.

Based on San Francisco Sentry Investment Group's 13F filing for Q2 2020, filed 17 Jul 2020.